Managing adverse events associated with sorafenib in renal cell carcinoma.
AffiliationThe Royal Marsden Hospital, London.
MetadataShow full item record
AbstractSorafenib, a multi-targeted kinase inhibitor, is approved in Europe for the treatment of patients with advanced renal cell carcinoma whose treatment with an interferon or interleukin-2-based therapy has previously failed, or who are unsuitable for such therapy. Unlike some first-generation anti-cancer therapies, sorafenib is generally associated with moderate and manageable adverse events. Some of the most common adverse events include a hand-foot skin reaction, diarrhoea and rash. As nurses provide an interface between the patient and the clinical team, it is important that they understand how sorafenib-related adverse events impact on patients. It is equally vital that nurses are able to recognize and manage these adverse events. Our experience has shown that with patient education, early reporting, monitoring and treatment, the adverse events of sorafenib therapy can be easily and effectively managed. Optimal adverse event management helps ensure treatment compliance and ensures that patients receive maximum benefit from therapy.
CitationManaging adverse events associated with sorafenib in renal cell carcinoma., 19 (1):58-60 Br J Nurs
JournalBritish Journal of Nursing
- Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
- Authors: Edmonds K, Hull D, Spencer-Shaw A, Koldenhof J, Chrysou M, Boers-Doets C, Molassiotis A
- Issue date: 2012 Apr
- Sorafenib: a promising new targeted therapy for renal cell carcinoma.
- Authors: Wood LS, Manchen B
- Issue date: 2007 Oct
- Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
- Authors: Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK
- Issue date: 2009 Nov
- Sorafenib in advanced clear-cell renal-cell carcinoma.
- Authors: Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group.
- Issue date: 2007 Jan 11
- Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
- Authors: Autier J, Escudier B, Wechsler J, Spatz A, Robert C
- Issue date: 2008 Jul